Long-Term Humoral and Cellular Immune Responses Elicited by a Heterologous Plasmodium vivax Apical Membrane Antigen 1 Protein Prime/Adenovirus Boost Immunization Protocol by Maduro Bouillet, Leoneide Erica et al.
INFECTION AND IMMUNITY, Sept. 2011, p. 3642–3652 Vol. 79, No. 9
0019-9567/11/$12.00 doi:10.1128/IAI.05048-11
Copyright © 2011, American Society for Microbiology. All Rights Reserved.
Long-Term Humoral and Cellular Immune Responses Elicited by a
Heterologous Plasmodium vivax Apical Membrane Antigen 1
Protein Prime/Adenovirus Boost Immunization Protocol
Leoneide E´rica Maduro Bouillet,1 Mariana Oliveira Dias,1 Nata´lia Alves Dorigo,1
Andrew Douglas Moura,1 Bruce Russell,7 Francois Nosten,8,9,10 Laurent Renia,7
E´rika Martins Braga,2 Ricardo Tostes Gazzinelli,3,6 Maurício M. Rodrigues,4
Irene S. Soares,5 and Oscar Bruna-Romero1,6*
Departments of Microbiology,1 Parasitology,2 and Biochemistry and Immunology,3 Institute of Biological Sciences, Federal
University of Minas Gerais, Brazil; Department of Clinical Analyses and Toxicology, Faculty of Pharmaceutical Sciences,
University of Sa˜o Paulo, Sa˜o Paulo, Brazil4; Department of Microbiology, Immunology and Parasitology, Federal
University of Sa˜o Paulo, Sa˜o Paulo, Brazil5; Rene´ Rachou Research Center, FIOCRUZ, Belo Horizonte, Minas
Gerais, Brazil6; Singapore Immunology Network, Biopolis, Agency for Science Technology and Research,
Singapore7; Shoklo Malaria Research Unit, Mae Sot, Tak, Thailand8; Center for Clinical Vaccinology and
Tropical Medicine, Churchill Hospital, Oxford, United Kingdom9; and Faculty of Tropical Medicine,
Mahidol University, Bangkok, Thailand10
Received 11 March 2011/Returned for modification 31 March 2011/Accepted 10 June 2011
Apical membrane antigen 1 (AMA-1) is an invasion-related Plasmodium antigen that is expressed during
both intracellular and extracellular asexual stages of the parasite’s life cycle, making it an ideal target for
induction of humoral and cellular immune responses that can protect against malaria. We show here that when
it is administered as a recombinant protein (P) in Montanide ISA720 adjuvant, followed by a recombinant
human type 5 adenovirus (Ad), intense and long-lasting Plasmodium vivax AMA-1-specific antibody responses
(including both IgG1 and IgG2a), as well as proliferative memory T cell responses, can be detected in
immunized mice. Memory T cells displayed both central (CD44hi CD62Lhi) and effector (CD44hi CD62Llo)
phenotypes, with the central memory phenotype prevailing (56% of AMA-1-specific proliferating cells). Con-
sidering the main traits of the memory immune responses induced against AMA-1, this particular sequence of
immunogens (P followed by Ad), but no others (Ad/Ad, Ad/P, or P/P), displayed an optimal synergistic effect.
These results give further support to the need for preclinical studies of P. vivax vaccine candidate AMA-1
administered in prime/boost protocols that include recombinant proteins and adenoviral vectors.
Plasmodium vivax is estimated to cause 80 to 310 million
cases of human malaria annually, mainly in the Middle East,
Asia, Western Pacific region, and Central and South America
(35, 40). Although P. vivax is widely regarded as benign, in
recent years there have been increasing reports describing se-
vere manifestations of vivax malaria in Indonesia (56), Papua
New Guinea (18), western India (26), and Brazil (49). Addi-
tionally, there has been renewed interest in the control of P.
vivax because recent studies have shown the emergence and
spread of drug-resistant strains in Asia, Brazil, and Africa (13,
23, 55). Thus, despite the fact that most malaria research
groups have traditionally focused on the development of vac-
cines against Plasmodium falciparum, which is responsible for
the most dangerous forms of malaria, there are good reasons
to develop a P. vivax vaccine.
Malaria vaccine candidates can derive from preerythrocytic
stages (free sporozoite or intracellular liver stage forms) or
blood stages (asexual or sexual) of the Plasmodium parasite. At
least in theory, if present in both stages, any antigen might have
better chances of becoming a vaccine, since it could become a
target for all known host protective immune mechanisms (cel-
lular and humoral). Apical membrane antigen 1 (AMA-1) is
present in both preerythrocytic and asexual blood-stage forms
of the Plasmodium parasite. Antibodies against this molecule
display inhibitory activities against sporozoite invasion of
hepatocytes (52) and against merozoite invasion of erythro-
cytes (24, 42).
Montanide ISA720 is an oil-in-water synthetic adjuvant that
has been repeatedly used in preclinical (4, 12, 15, 20) and
clinical (17, 19, 21, 28, 32, 37, 38, 46, 50) trials of different
malaria vaccine candidates and in particular of P. falciparum
AMA-1 (11, 12, 15, 21, 32, 38, 46, 50). It is highly immunogenic
and is able to induce significant humoral and cellular immune
responses, even after a single immunization, although standard
protocols consist of three doses of antigen in this adjuvant.
Although it seems to be a safe adjuvant for human use, reac-
togenicity has been reported in some cases (21, 38, 46). If
included in a prime/boost protocol in which two or more im-
munogens are sequentially administered, the number of doses
of this adjuvant/antigen combination might be decreased,
maintaining immunogenicity and increasing its safety.
Recombinant adenoviruses are efficient vectors to simulta-
neously induce antigen-specific humoral and cellular immune
responses in immunized hosts. Our previous work has shown
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that homologous prime/boost protocols that use this vector to
immunize mice are effective against Leishmania spp. (43), Toxo-
plasma gondii (10), or Trypanosoma cruzi (31) infections; they
are all highly dependent on the induction of T-cell immunity
for protection. Parasite-specific antibodies were also induced
in all those animals. More than a decade ago we also described
a heterologous prime/boost protocol that combined recombi-
nant adenoviral and poxviral (vaccinia virus) recombinants,
which was able to induce potent humoral and cellular re-
sponses and completely protect mice against murine malaria
caused by Plasmodium yoelii (8). To date, human adenovirus
type 5 (Ad5) vectors have also demonstrated an exceptional abil-
ity to generate cellular immune responses against recombinant
antigens in humans (9), although some authors have questioned
the possibility of their use because of preexisting immunity de-
tected in a some humans (33, 53). If included in a prime/boost
protocol, a single dose of adenovirus(es) might be sufficient for
vaccination, even in individuals with preexisting immunity.
Three recent reports have also shown good immunogenicity
of P. falciparum AMA-1 when encoded by adenoviral vectors.
Bruder et al. (7) were able to induce P. falciparum-specific
antibodies in rabbits immunized with an AMA-1 recombinant
adenovirus type 5 vector that inhibited 99% of parasite growth
in vitro. Sedegah et al. (51) showed that human volunteers
immunized with an equivalent vector generated CD8 T cells
that specifically recognized P. falciparum AMA-1 peptides in
gamma interferon (IFN-) assays. Finally, Draper et al. (14) im-
munized monkeys using a simian adenoviral vector (AdCh63) in
different prime/boost protocols and were able to induce P. falcip-
arum AMA-1-specific T and B cell immune responses. However,
the authors did not report any result of a protocol consisting of
protein priming and an adenovirus booster.
In our current study we have pursued the idea that to
achieve longer-lasting simultaneous B and T cell immune re-
sponses against P. vivax, a heterologous prime/boost immuni-
zation regimen that includes inoculation of the AMA-1
(PvAMA-1) protein in a purified form, preceded or followed
by an adenovirus-vectored antigen (Ad5PvAMA-1), could be
one of the best approaches. PvAMA-1 was administered as a
recombinant protein purified from bacteria in Montanide
ISA720, aiming mainly at the induction of a strong humoral
response. The recombinant human type 5 adenovirus vector
was used not only to induce a humoral response but also to
generate an efficient T cell response. The antigen-specific ef-
fector and memory immune profiles detected after these im-
munizations are described below.
MATERIALS AND METHODS
Recombinant immunogens. Recombinant PvAMA-1 represents a His6-tagged
polypeptide (amino acids [aa] 43 to 487) of a P. vivax isolate from Belem, Brazil
(named BEL 12), as previously described (45). Recombinant PvMSP-119 repre-
sents a His6-tagged C-terminal 19-kDa fragment (aa 1616 to 1704; GenBank
accession number M60807) of Plasmodium vivax Belem strain merozoite surface
protein 1. Both proteins were expressed in Escherichia coli and purified using
Ni2 columns (ProBond; Invitrogen). AMA-1 was purified under denaturing
conditions and MSP-119 under native conditions.
The PvAMA-1-encoding sequence fused to that of the signal peptide of the
hemagglutinin of influenza virus (HASS) was also cloned into an adenoviral
shuttle vector (pAdCMV), which was further cotransfected with plasmid pJM17
into HEK-293 cells (CRL-1573; American Type Culture Collection [ATCC],
Manassas, VA) as previously described (34), to generate replication-deficient
human type 5 recombinant adenovirus Ad5PvAMA-1. Individual clones of this
virus were analyzed for recombinant protein expression. Positive clones were
purified using a Vivapure Adenopack kit (VivaScience) and kept frozen at
80°C. Viral concentrations were calculated as viral particles (vp) and PFU per
milliliter, by spectrophotometry and plaque assays, respectively. vp/PFU ratios
were equivalent for the two batches of viruses used in this study (90 to 95 for
Ad5PvAMA-1 and 76 to 83 for Ad5lacZ).
Animals and immunization regimens. Female BALB/c mice were bred at the
CEBIO/UFMG animal facilities in Belo Horizonte, Brazil, and used according to
our institutional ethical guidelines (certificate CETEA 140/2005). Purified re-
combinant proteins formulated in Montanide ISA720 (Seppic, France) were
administered subcutaneously to BALB/c mice over 8 weeks old (20 g of
PvAMA-1 per animal) in a final volume of 100 l. Ad5PvAMA-1 was adminis-
tered subcutaneously (109 PFU/animal) to littermates into both sides of the tail
in a final volume of 100 l. When needed, animals were boosted within a 6-week
interval with the same doses of recombinant adenovirus or protein in Montanide
ISA720. A minimum of 6 animals per group were used in all experiments.
The subcutaneous route was chosen for administration of both immunogens
because previous studies had shown similar efficiency and fewer harmful effects
compared to other routes (29, 44).
IFA. Indirect immunofluorescence assay (IFA) was performed on HEK-293
cells infected with Ad5PvAMA-1 or with a control virus (Ad5lacZ) at a multi-
plicity of infection (MOI) of 5 for 36 h. Cells were then fixed with 4% parafor-
maldehyde and permeabilized with 0.2% Triton X-100. Sera of mice (Ad5 pre-
adsorbed) immunized with different vaccination protocols or of human patients
(Ad5 negative) from areas where malaria is endemic (Ethics Committee on
Research with Humans of Universidade Federal de Minas Gerais, Protocol
ETIC 060/07) were diluted in phosphate-buffered saline (PBS) containing 3%
bovine serum albumin (BSA) and used as sources of primary PvAMA-1-specific
antibodies. Secondary Alexa Fluor 488-conjugated anti-mouse IgG or anti-hu-
man IgG antibodies (Invitrogen) were diluted 1:200 in PBS containing 3% BSA.
Slides were finally washed, mounted, sealed with Prolong Gold antifade reagent
containing 4,6-diamidino-2-phenylindole (DAPI) (Invitrogen), and observed us-
ing a fluorescence microscope.
Samples of P. vivax-infected blood from malaria patients were collected after
written informed consent (Ethics Committee of the Faculty of Tropical Medi-
cine, Mahidol University, Thailand, certificate of ethical approval MUTM 2010-
006-01 and University of Oxford, Centre for Clinical Vaccinology and Tropical
Medicine, United Kingdom, OXTREC 027-025) was obtained and were pro-
cessed within 5 h of collection at Shoklo Malaria Research Unit, Thailand. White
blood cells and platelets were removed, and infected erythrocytes were cultured
to the late schizont stage in 2% hematocrit (Hct)–McCoy’s 5A medium supple-
mented with 2.4 g/liter D-glucose, 40 mg/ml gentamicin sulfate, and 20% heat-
inactivated human AB serum in an atmosphere of 5% O2 at 37.5°C for 22 to 44 h
(48). Thin-smear preparations of free merozoites and mature schizont-infected
erythrocytes were fixed with cold acetone for 15 min and blocked with 3% BSA
in PBS for 30 min at 37.5°C in a humidified incubator. PvAMA1-immunized or
prebleed mouse serum (1:100) was then applied to the smear and incubated for
1 h before incubation with the secondary anti-mouse IgG antibody conjugated to
Alexa Fluor 488 (Molecular Probes) or DAPI as described above. The presence
of PvAMA1 was visualized using a Nikon TS100 epifluorescence microscope.
Enzyme-linked immunosorbent assay (ELISA). Purified PvAMA-1 protein ex-
pressed in E. coli was used as plate-coating antigen (Nunc MaxiSorp) at a concen-
tration of 0.5 g/well. Nonspecific binding sites were blocked with 2% dry milk in
PBS. Serial dilutions of individual sera (1:100 to 1:409,600) were added to the wells
and incubated for 1 h. The reaction was developed using horseradish peroxidase-
conjugated (Zymed, Life Technologies) secondary antibodies (anti-IgG, IgG1, and
IgG2a) and 3,3,5,5-tetramethylbenzidine (TMB) (Pierce) substrate. Optical densi-
ties were measured at 450 nm in a Titertek microplate reader (McLean, VA).
T cell proliferation and cytokine detection. Spleens were aseptically isolated
from mice at the times indicated. Splenocytes (106 cells/well) were stained with 4
carboxyfluorescein succinimidyl ester (CFSE) for 15 min at 37°C in 5% CO2 and
then stimulated with PvAMA-1(1 g/ml) or with an equivalent concentration of
control protein (PvMSP-119) in Dulbecco modified Eagle medium (DMEM) (Invit-
rogen) supplemented with 5% fetal calf serum (FCS) and 4 g/ml gentamicin.
Cultures were incubated for 30 or 48 h (as indicated) before T cell proliferation was
determined by flow cytometry. Analyses were performed with a FACScan flow
cytometer (Becton Dickinson, Oxford, United Kingdom). CFSE-labeled splenocytes
were stained before analyses with fluorochrome-conjugated antibodies against CD4
(allophycocyanin [APC], clone GK1.5) and CD62L (phycoerythrin [PE], clone
MEL-14) or CD44 (PE, clone IM7) from BD Pharmingen.
Cytokines in cell culture supernatants were measured at 48 h after addition of
1 g/ml of PvAMA-1 using anticytokine sandwich antibodies of the correspond-
ing ELISA kits (R&D systems).
VOL. 79, 2011 IMMUNOGENICITY OF P. VIVAX AMA-1 PRIME/BOOST 3643
Statistical analyses. Analysis of variance (ANOVA) was used for comparison of
groups. For analysis of groups with a normal distribution of samples, we also used
the Student t test. When data did not follow a normal distribution, nonparametric
tests (Kruskal-Wallis or Mann-Whitney) were applied. Variances were compared
using Bartlett and de Levene tests. A significance level of 5% was used in all cases.
For nonhomogeneous variances, Welch’s correction was applied for parametric
analyses. For multiple comparisons (Student t test and Mann-Whitney test), Bon-
ferroni’s correction was applied to avoid overestimated global errors. For flow
cytometry analyses, the Z test was used to compare two proportions.
RESULTS
Recombinant forms of PvAMA-1 used in this study and
reactivity with anti-Plasmodium antibodies present in malaria
patients or immunized mice. Two recombinant forms of the P.
vivax vaccine candidate AMA-1 were used in our study (Fig.
1A): a recombinant protein generated in recombinant E. coli
bacteria and a recombinant human type 5 adenoviral vector.
Expression of Pv-AMA-1 was efficiently induced in bacteria
(Fig. 1B, left panel), being affinity purified to the point of
displaying a single band of the expected molecular mass
(around 60 kDa) after SDS-PAGE analysis (Fig. 1B, middle
panel). Furthermore, a single reactive band of the same ap-
parent molecular mass, which bound human antibodies raised
after natural contact with P. vivax parasites, could be observed
when the reactivity of the pure recombinant protein was tested
by immunoblotting using sera of malaria patients (Fig. 1B,
right panel).
A recombinant adenovirus expressing the ectodomain of
PvAMA-1 (regions I, II, and III) (45) was also constructed. As
FIG. 1. Recombinant immunogens used in this study and reactivity with human antibodies. (A) Scheme of the engineered extracellular domains
I to III of P. vivax AMA-1 as expressed by an adenovirus (AdPvAMA-1) or E. coli (PvAMA-1). SP, signal peptide; HASS, influenza virus
hemagglutinin signal sequence. (B) AMA-1-containing bacterial lysates after IPTG (isopropyl--D-thiogalactopyranoside) induction (left panel),
pure protein (middle panel), and specific reactivity with a P. vivax-positive human serum in an immunoblot assay (serum dilution, 1:2,000) (right
panel). (C) Reactivity of the same serum (1:200 dilution) with HEK-293 cells infected with AdPvAMA-1 or a control adenoviral vector. Cells were
visualized by fluorescence microscopy or phase-contrast light microscopy at a magnification of 600.
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depicted in Fig. 1A, cells infected with this vector express the
recombinant protein fused to the signal peptide of the influ-
enza virus hemagglutinin protein (HASS) to facilitate secre-
tion and thus antibody generation, as well as cross presentation
of antigens to T cells.
Antibodies to AMA-1 are found in most people exposed to
malaria, and the levels of IgG to PvAMA-1 increase with the
time of exposure (36). To characterize the recombinant prod-
uct generated by Ad5PvAMA-1-infected cells, immunofluores-
cence assays were performed using human sera of malaria
patients (who tested Ad5 negative) as a source of primary
antibodies (Fig. 1C). Figure 1C shows that HEK-293 cells
infected with Ad5PvAMA-1 generate a recombinant product
that resembles the parasite’s native antigen, since it is strongly
recognized by antibodies present in individuals naturally ex-
posed to P. vivax parasites.
Antibodies are directly linked to protection against the blood
stages of the malaria parasite. To determine whether immuniza-
tion with the recombinant forms of P. vivax AMA-1 could induce
antibodies with specificities similar to those induced against the
parasite itself, we performed an indirect immunofluorescence as-
say using P. vivax parasites (free merozoites and infected eryth-
rocytes) and also compared the cross-reactivity between AMA-1-
specific immunization-induced (murine serum) and parasite-
induced (human serum) antibodies.
Initially, parasite isolates from infected patients were in-
duced to mature in vitro before thin smears were prepared,
fixed, and incubated with sera of BALB/c mice immunized with
109 PFU/animal of Ad5PvAMA-1 or 20 g of PvAMA-1 pro-
tein in Montanide ISA720. Intense and specific fluorescence
could be observed in free merozoites when incubated with sera
of either adenovirus- or protein-immunized mice (Fig. 2A) but
not when incubated with control sera (not shown). Of interest,
little or no fluorescence was observed inside infected erythro-
cytes within these preparations.
Sera of the same groups of mice were also tested by immu-
nofluorescence against Ad5PvAMA-infected cells (Fig. 2B) as
well as by ELISA using PvAMA-1 coated plates (Fig. 2C).
Antibodies induced in mice by Ad5PvAMA-1 or PvAMA-1
recognized the P. vivax antigen expressed by HEK-293 cells
with a similar fluorescence pattern, suggesting an overall sim-
ilarity in structure between both forms of the antigen and,
together with the results shown above, a similarity between
these antigens and the native parasite molecule.
To determine whether cross-reactivity also existed when us-
ing bacterially expressed PvAMA-1, we further analyzed by
ELISA, using PvAMA-1-coated plates, the sera of control-,
Ad5PvAMA-1-, and PvAMA-1-immunized mice at 2 and 5
weeks after immunization (Fig. 2C). The plot shows that, al-
though the intensities were different (PvAMA-1 in Montanide
ISA720 induced significantly higher levels of antibodies after a
single immunization [P 	 0.01 by Kruskal-Wallis test), reac-
tivity was specific for PvAMA-1 independently of the immuno-
gen used for inoculation.
Humoral immune responses induced by different PvAMA-1
immunization regimens. The intensities of AMA-1-specific hu-
moral responses induced by immunization were subsequently
determined in all groups of mice. We first measured, at 2 weeks
after immunization, the antibody responses induced by differ-
ent single-dose or prime/boost vaccination regimens. It has
been repeatedly shown by many authors that different orders
of administration of different immunogens may result in com-
pletely different immunization outcomes. Thus, our immuni-
zation protocols included inoculations of the recombinant pro-
tein and the adenoviral vector in different orders (Fig. 3A).
The immunization interval used was 6 weeks, because we pre-
viously determined that this interval is the minimum possible
to avoid significant activation-induced cell death (AICD)
mechanisms that could blunt immune responses before they
reach maximal expansion (8).
An ELISA was used to evaluate the humoral immunogenicities
of the different immunization protocols in the different groups of
mice. Optical densities were measured and total IgG antibody
titers determined after endpoint dilutions of the sera of immu-
nized BALB/c mice, at 2 weeks after inoculation of the last dose
of experimental vaccine, using plates coated with PvAMA-1. The
results (Fig. 3B) show that homologous and heterologous prime/
boost protocols were able to elicit specific humoral responses that
were in all cases more immunogenic than single-dose immuniza-
tion protocols (P 	 0.01 by Kruskal-Wallis test). Not all relevant
protocols were equivalently immunogenic. Thus, reactivity (mea-
sured as total optical density in arbitrary units) and antibody titers
were significantly higher (all P values 	 0.01 by Mann-Whitney
test) in sera of animals immunized with PvAMA-1 (P) alone or
initially presented as a recombinant protein followed by either the
adenoviral vector (P/Ad) or the same protein (P/P) than in groups
of animals that received an initial dose of Ad5PvAMA-1 (Ad,
Ad/Ad, or Ad/P). Antibody levels induced by P/Ad and P/P were
not statistically different.
Memory antibody titers were also determined, at 14 weeks
after inoculation of the last dose of experimental vaccine. By
that time, we could observe significantly higher (P 	 0.05 by
Mann-Whitney test compared to primed-only mice) long-term
(memory) responses still present in prime/boost-immunized
animals. The highest antibody titers were displayed by sera of
mice immunized with the P/Ad protocol.
PvAMA-1-specific antibody subclasses during effector and
memory responses. To explore the immune profiles induced in
mice by the different immunization protocols, we first measured
the levels of IgG1 and IgG2a antibodies in the sera of the differ-
ent groups of mice. Total reactivity was higher for IgG1 than for
IgG2a in all groups except Ad/Ad-immunized mice at both 2 (Fig.
3C) and 14 (Fig. 3D) weeks after immunization. However, al-
though less intense in most groups, significant IgG2a reactivity
was detected in all animals, suggesting a mixed Th1 and Th2
response. At 3 months after immunization, high levels of circu-
lating IgG1 and IgG2a antibodies were still present in the blood,
which indicated that immune memory had been potently induced
for both subtypes. However, memory IgG1 responses decreased
proportionally faster than IgG2a in the groups that received pro-
tein in Montanide as the first immunogen.
Of interest, a comparison of IgG isotype reactivities also
showed significant differences in memory generation between
immunization protocols. Thus, the protocol that used
Ad5PvAMA-1 as a booster immunogen for PvAMA-1 (P/Ad)
induced significantly (P 
 0.0016 by Mann-Whitney test) more
potent memory immune responses (both IgG1 and IgG2a)
than a booster dose of the same protein (P/P).
Cellular immune responses induced in mice by vaccination
with recombinant forms of P. vivax AMA-1. Antibodies that
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block red blood cell invasion seem to be the main mediators of
protection against the blood stages of Plasmodium. However,
the generation of AMA-1-specific T cells in the immunized
host could also be relevant, both for long-term maintenance of
the humoral response (memory cytokine-producing T helper
cells) and for a possible induction of protection against the
liver stages of the parasite (mainly through antigen-specific
production of IFN-). To address this, splenocytes of mice
FIG. 2. Reactivity of antibodies generated by immunization of BALB/c mice with a P. vivax AMA-1 recombinant adenovirus or with E. coli-produced
AMA-1 protein in Montanide ISA720. (A) IFA images (magnification,1000) representing the immune reactivity of sera (1:100 dilution) of immunized
mice (green) or the nucleic acid stain DAPI (blue) with P. vivax parasites or parasitized erythrocytes (light) obtained from infected individuals. (B and
C) Cross-reactivity of mouse antibodies induced by immunization with either relevant immunogen (Ad or P) or with a control adenovirus against
AdPvAMA-1-infected cells (IFA, 1:200 serum dilution; magnification,600) (B) or against PvAMA-1 protein used to coat an ELISA plate (1:400 serum
dilution) (C). Results are representative of at least two equivalent experiments performed with pools of three animal sera.
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immunized with the different prime/boost protocols were
stained with CFSE and CD4-APC 2 weeks after receiving the
last immunizing dose, and their proliferation rates were ana-
lyzed by flow cytometry. The specificity of the responses was
assessed by comparing proliferation rates of cells from AMA-
1-immunized mice with those of cells from mice inoculated
with an irrelevant antigen (-galactosidase administered as
recombinant adenovirus Ad5lacZ), as well as by restimulating
splenocytes of AMA-1-immunized mice with PvAMA-1 or with
a different P. vivax antigen, MSP-119.
As illustrated in Fig. 4, when splenocytes were analyzed 30 h
after ex vivo antigenic stimulation, CD4 T lymphocyte prolif-
eration was observed in all groups of mice immunized with
recombinant forms of AMA-1 (comparison of proportions,
P 	 0.05 by Z test). Lymphocytes of animals that received two
immunizations of either form of the antigen proliferated more
intensely than those from animals that received a single im-
munizing dose (P 	 0.05 by Z test), confirming that prime/
boost protocols are more efficient at inducing not only anti-
bodies but also T cell responses. No statistically significant
differences could be observed among different prime/boost
protocols, although higher percentages of proliferating cells
were always detected in the groups that were inoculated with
PvAMA-1 in Montanide ISA720 as the priming formulation
(P/Ad and P/P).
Lymphocytes were also stained with CFSE and antibodies to
surface markers CD4, CD62L, and CD44, at 14 weeks after the
last immunization, to determine the type and fate of the mem-
ory T cells that could had been generated in BALB/c mouse
littermates. Figure 5 shows that CD4 splenocytes from all
groups of mice that received prime/boost immunizations also
proliferated intensely at this time point in the presence of
AMA-1 (compare top and second rows of panels). Prolifera-
tion was significantly more intense (P 	 0.05 by Z test) for the
groups of mice that received PvAMA-1 in Montanide ISA720
as the priming immunogen (P/Ad and P/P in the fourth row of
panels) than for groups that received Ad5PvAMA-1 adenovi-
ruses (Ad/Ad or Ad/P, same row).
According to the literature, central memory (CM) and ef-
fector memory (EM) T cell phenotypes may be defined, re-
spectively, as CD44hi CD62Lhi and CD44hi CD62Llo (6). When
memory phenotype cell surface markers were analyzed in mice
at 14 weeks after immunization, it could be observed that the
vast majority (mean standard deviation
 95% 2%) of the
proliferating cells were CD44hi (compare the third and fourth
rows of panels in Fig. 5). The second activation marker ana-
lyzed, CD62L, however, was not expressed in all proliferating
cells. Figure 5 shows that mean values of CD62Lhi proliferating
cells (second row) versus total proliferating cells (fourth row)
were 61, 56, 37, and 40%, respectively, for the Ad/Ad, P/Ad,
Ad/P, and P/P groups. This indicates that a significant propor-
tion of proliferating cells were CD62Llo and suggests the in-
duction of immune responses with a mixed memory phenotype,
with the CM phenotype prevailing (significant difference with
FIG. 3. Effector and memory humoral immune responses elicited in BALB/c mice after prime/boost immunizations with combinations of
AdPvAMA-1 (Ad) and PvAMA-1 (P) or with the control formulation (Ctrl). (A) Scheme of immunizations and sample collection times.
(B) ELISA results (both optical densities at 2 weeks after immunization and antibody titers at 2 and 14 weeks after inoculation of the last dose
of either experimental vaccine) as determined in the sera of mice. (C and D) IgG1 and IgG2a responses in the sera of immunized mice at 2 (C) and
14 (D) weeks after inoculation of the last immunizing dose. Results are representative of three different experiments performed with 6 animals
per group individually analyzed.
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a confidence level of 99% by the Z test) when the Ad vector is
used to boost immunes responses and the EM phenotype pre-
vailing when the P is given as booster.
Cytokine secretion profiles of splenocytes of mice vaccinated
with recombinant forms of P. vivax AMA-1. Supernatants of
splenocyte cultures from mice that had been immunized 14
weeks before with the different protocols mentioned above
were analyzed by sandwich ELISA to determine their cytokine
secretion profiles after in vitro restimulation with recombinant
PvAMA-1. Figure 6A shows that splenocytes of all groups of
animals that received booster doses of either immunogen were
capable of secreting higher levels of IFN- than those of ani-
mals that received a single dose. However, highly significant
differences were observed only when using the P/Ad immuni-
zation protocol. The amounts of IFN- secreted by splenocytes
of mice immunized with this protocol were repeatedly found to
be at least two times higher than those secreted by splenocytes
from animals immunized with P/P and up to three times higher
than those of animals that received a single dose of protein in
Montanide ISA720. Figure 6B shows that, opposite to that
observation, interleukin-4 (IL-4) secretion was not significantly
increased by administration of a booster dose of either im-
munogen, though the technique was performed with a range of
values that would have detected those differences. Finally, Fig.
6C shows that IL-10 was produced at significantly higher levels
by splenocytes of mice that had received booster doses of
either immunogen, being significantly higher in animals immu-
nized with either the homologous (P/P) or the heterologous
(P/Ad) protocol.
DISCUSSION
We have used two different systems (E. coli and a human
type 5 adenovirus vector) to express P. vivax AMA-1. Ad5 was
chosen because in the absence of preexisting immunity (which
is the case for most children during the first months of life,
when they would be considered primary targets for the vac-
cine), it is the most immunogenic among several adenoviral
FIG. 4. Proliferation assay performed on CFSE-labeled splenocytes of BALB/c mice immunized with P. vivax recombinant immunogens. The
percentage of proliferation was calculated by flow cytometry on CD4 gated splenocytes of mice immunized 2 weeks before with AMA-1
(continuous lines) administered as a recombinant adenoviral vector (Ad), as a protein in Montanide ISA720 (P), or as sequential inoculations of
both immunogens in prime/boost protocols, compared to mice immunized with two doses of an irrelevant adenovirus control (dotted lines).
CFSE-labeled splenocytes were induced to proliferate ex vivo for 30 h by adding PvAMA-1 to the cell culture. Plots are representative of two
different experiments that included a total of six animals per group, analyzed in pools of three. Numbers represent mean values of the results.
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vectors tested to date (1, 2). Additional adjuvants were avoided
in the adenoviral formulation to maintain the immune traits
characteristic of the Ad5 vector. Our results indicate that both
systems generated AMA-1 successfully, since recombinant
products of the expected molecular weight specifically reacted
with antibodies from individuals previously exposed to P. vivax
parasite antigens.
In immunized mice, the recombinant protein, as well as the
adenoviral vector, induced specific antibody responses against
P. vivax parasites. Of interest, antibodies raised by our immu-
nizations reacted strongly with free merozoites but not detect-
ably with intraerythrocytic parasites, a phenomenon already
described by members of our group (16). Cross-reactivity be-
tween the protein produced in bacteria and the antigen ex-
pressed in adenovirus-infected cells suggests that the structure
of the polypeptide is largely conserved between the two recom-
binant products. Moreover, the immune reactivity and fluores-
cence patterns displayed by adenovirus-infected cells incu-
bated with sera of human malaria patients or immunized mice
suggest that the overall structure must also be conserved be-
tween the recombinant and the native parasite antigens.
We next compared the humoral and cellular immune re-
sponses induced in mice immunized with different homologous
or heterologous prime/boost protocols involving the recombi-
FIG. 5. Memory phenotypes of AMA-1-specific mouse lymphocytes generated after prime/boost vaccination. The percentage of CD62L- or
CD44-positive proliferating cells (as indicated) was determined by flow cytometric analyses of splenocytes of BALB/c mice immunized according
to the most relevant prime/boost protocols defined in this study and tested 14 weeks after the final immunization. CFSE-labeled splenocytes were
induced to proliferate ex vivo for 48 h by adding PvAMA-1 (three lower rows of panels) or PvMSP-119 (negative controls, upper row of panels)
to the cell cultures. Results are representative of two different experiments involving a total of six animals per group, individually analyzed.
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nant purified AMA-1 protein produced in bacteria and the
nonreplicative recombinant adenoviral vector. A single immu-
nization with the purified protein in Montanide ISA720 or with
the recombinant adenovirus induced readily detectable IgG
antibodies. Antibody titers were higher when using PvAMA-1
in Montanide ISA720. In all cases, booster immunizations
were able to increase the antibody titers detected after a single
administration of either immunogen. When the efficiencies of
different prime/boost protocols were compared, the results
demonstrated that immunizations with P/P (homologous) and
P/Ad (heterologous) protocols were the most efficient at en-
hancing antibody responses. These responses not only were
high at the active phase of the immune response (2 weeks after
immunization) but also remained high for over 3 months (14
weeks) after the boost. It is worth noting that, at any time point
considered, vaccination generated parasite-specific antibodies
more efficiently than repeated natural human infections (45).
The prime/boost protocol P/Ad described here is particu-
larly attractive not only because it displayed higher immuno-
genicity but also because it could represent a significant step up
in vaccine safety. Previous human vaccination protocols, such
as the administration of three doses of a protein or peptide in
Montanide ISA720 (19, 32, 37, 38, 46, 50) or three doses of a
recombinant adenovirus (9), could be improved by using only
one dose of each immunogen, and this would eliminate the
possibility of adverse effects resulting from administration of
repeated doses. In addition, it has been suggested (5) that a
heterologous protocol could overcome preexisting immunity to
adenovirus type 5 vectors present in human populations as well
as avoid the altered immune responses to the recombinant
antigens observed in these populations when immunized with a
homologous Ad5 prime/boost protocol (39).
Our results in mice indicate that immunization with
PvAMA-1 was capable of inducing long-lasting mixed humoral
responses, with production of both IgG1 and IgG2a antigen-
specific antibodies. ELISA reactivity suggested that IgG1 was
initially produced more than IgG2a, though levels were very
similar at week 14 after boost. Other authors have also ob-
served a preferential induction of antibodies of the IgG1 sub-
class when vaccinating with Montanide ISA720, in both mice
(41) and humans (3). The induction of not only IgG1 but also
IgG2a responses is important, since in malaria, as in all infec-
tious diseases, antibody isotypes affect pathogen neutralization
and clearance, and it is widely accepted that cytophilic anti-
bodies (such as mouse IgG2a) are involved in protective im-
munity against Plasmodium AMA-1 and other blood-stage an-
tigens (22, 36).
The generation of antigen-specific T cells was also analyzed,
and the results showed that not-yet-described T cell epitopes
for the mouse H-2d/major histocompatibility complex (MHC)
background must be present in the P. vivax AMA-1 antigen,
since intense T cell proliferation was observed when spleno-
cytes of immunized BALB/c mice were restimulated in vitro
with this antigen. Although a description of mouse T cell
epitopes is not very relevant for human studies because of the
significant differences in MHCs between the two species, it is a
good indicator of the capacity of the adenoviral vector to
induce efficient T cell responses. In fact, a recently published
paper (51) describes for the first time the induction in humans
of CD8 T cells against nine epitopes of P. falciparum AMA-1
FIG. 6. Cytokine secretion profiles of splenocytes of BALB/c mice
immunized with P. vivax recombinant immunogens. The cytokines IFN-
(A), IL-4 (B), and IL-10 (C) were analyzed by ELISA in cell culture
supernatants after in vitro restimulation with recombinant PvAMA-1 of
splenocytes of the different groups of mice (as indicated) immunized 14
weeks before. Plots are representative of two different experiments that
included a total of six animals per group, analyzed in pools of three.
Numbers represent means  standard errors of the means (SEM).
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after immunization of volunteers with an adenoviral vector
equivalent to the one described here.
Contrary to what has been previously described for adeno-
virus-induced T cells, we could detect the preferential induc-
tion of CM T cells after immunization with P/Ad or Ad/Ad.
Since the preferential induction of CD8 T cell EM responses
has been attributed to the fact that the recombinant adenoviral
vector may persist in the host organism for long times (54), it
could be the case that a previous immunization with the re-
combinant protein or with the same vector may have acted as
an adenovirus clearance stimulus, permitting the preferential
induction of a different type of memory cells. Alternatively,
slight differences in adenovirus backbones, i.e., deletions of
genes encoding products that may interfere with immune re-
sponses against the vector, may result in different persistence
of the resulting vectors, affecting the profile of memory gen-
eration.
As expected from the literature (30, 57), the order of ad-
ministration of the immunogens affected the humoral and cel-
lular responses elicited. Thus, when Ad was used as a priming
vaccine, the antibody titers and proliferative T cell rates were
lower than when the same vector was used as a booster. A
recent study by Radosevic et al. (41) explored the use of a
recombinant P. falciparum antigen (the circumsporozoite pro-
tein) expressed in yeast for priming and two adenoviruses
(Ad35 and Ad26) as boosters. Although the parasite, the an-
tigen, and the viruses studied were different, results were sim-
ilar to those shown here for PvAMA-1. A recent report by
Draper et al. (14) suggests that an adenovirus priming followed
by a protein booster (Ad/P) would be the most efficient pro-
tocol to induce B cell responses against PfAMA-1; however, no
final conclusions can be extracted from these data since the
authors did not include P/Ad among the prime/boost protocols
compared. In any case, all three studies with recombinant
adenoviruses encoding PfAMA-1 reported to date (7, 14, 51)
have reported antibody titers capable of significantly inhibiting
P. falciparum growth in culture, greatly supporting our current
approach to develop a vaccine against P. vivax.
This is the first time to our knowledge that any recombinant
virus encoding P. vivax AMA-1 has been described and used to
induce immune responses specific against this parasite. Few
studies on experimental vaccination with PvAMA-1 have been
performed. In summary, researchers have described high an-
tibody titers following immunization with recombinant pro-
teins (16, 27) and lower titers when using plasmid DNA vac-
cines (25, 47). In none of these studies did the authors compare
two or more different protocols or use a recombinant adeno-
virus vector. Therefore, to date it is not possible to compare
our results with others. Additionally, this lack of sufficient data
also impedes any conclusion on the important relationship
between allelic polymorphism and immune recognition of
AMA-1. Despite that, our results suggest that both humoral
and cellular memory responses are potently induced in mice
when the P/Ad immunization protocol is used. Not only were
antibody levels (both IgG1 and IgG2a) potently induced, but
also more memory (CM and EM) T cells were present nearly
4 months after this immunization. Simultaneous induction of B
and T cell responses against AMA-1 is important, since this
liver- and blood-stage antigen may be target of both immune-
effector arms, which can help in neutralizing/clearing Plasmo-
dium parasites. Monkey experiments are underway to define
the safety, immunogenicity, and protective efficacy of this
prime/boost protocol.
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